Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

Additional information
Additional Information
Market: ASX
Sector: Pharma & Biotech
Epic: QRX
News: Latest news
Web Site: QRxPharma Ltd
Other Articles: 06-01-201010-12-200913-11-2009

RSS - Subscribe to the News Today on Proactive UK ▼

Friday March 12, 08:50Baobab Resources resumes drilling at Tete iron-vanadium-titanium project

Shares in the company were lifted by the news it started a 12,000 metres scout drilling campaign at its project in Mozambique, with constant updates expected in the next few months.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive NA ▼

Friday March 12, 07:58Lithium and rare earths markets poised for growth

Right now, the world relies almost completely on China for its rare-earth supply. The Chinese have made it clear that they want to keep more supply for themselves as they try to be the world leader in green technology

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Friday March 12, 07:51White Energy enters coal deal with China Guodian Group

White Energy Company (ASX: WEC; OTCQX: WECFY) has inked a non-binding heads of agreement with state owned Guodian Inner Mongolian Energy Sources Co Limited to develop a coal upgrading [...]

FULL ARTICLE ►
QRxPharma Ltd

QRxPharma Ltd

QRxPharma Limited (ASX: QRX; OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.  The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales.  QRxPharma’s lead drug compound, MoxDuo™ IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

 

CLICK HERE FOR FULL ANALYSIS OF QRXPHARMA LTD
Thursday, December 10, 2009

QRxPharma to launch acute pain drug in 2011

company news image

QRxPharma (ASX: QRX, OTCQX: QRXPY) said it expects to complete Phase 3 trials for its acute pain compound MoxDuo™IR by Q3 2010.

John Holaday, managing director said the company planned to file a New Drug Application approval by the US Food and Drug Administration for MoxDuo™IR by EOY 2010.

During 2010, in parallel it would progress discussions with strategic partners.

He said the company planned to launch MoxDuo™ IR into the acute pain segment of the US$12 billion global marketplace in 2011.

An underwritten A$21.6 million capital raising at 81c per share is underway to advance Phase 3 drug development for MoxDuo™ IR through NDA filing.  A placement, which was significantly oversubscribed, had raised A$8.0 million, and a rights issue will raise an additional A$13.6 million.

QrxPharma shares last traded at 81.5c.

AddThis Feed Button
Register here to be notified of Proactiveinvestors One2One Forums.

Other QRxPharma Ltd articles


Other QRxPharma Ltd news

More news ►

Investors interested in QRxPharma Ltd recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.